ACHC

Analyst Note: ACHC (Acadia Healthcare Company, Inc.)

Date: 2026-06-13 Current Price: $24.87

1. Structural Readiness

State: Context-only Conservative Entry: — Current Price: $24.87 Extension: — ATR at Breakout: — ATR Current: 5.1% (High) Pivot Strength: —

Analysis:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None Named

At this date, there is no named secular macro thesis driving this specific setup. This is a TACTICAL, setup-led name. The conviction must be derived strictly from the quality of the structural setup (the forming coil) and the immediate business fundamentals reported by management. We do not invent a thesis; we judge the name on its ability to execute its current guidance and the structural integrity of its price action. The absence of a named secular theme means the trade relies entirely on the company's operational delivery and the technical breakout confirmation.

3. The Business

Company Overview: Acadia Healthcare Company, Inc. is a holding company operating a network of behavioral healthcare facilities across the United States and Puerto Rico. As of March 31, 2026, the company operated 275 facilities with approximately 12,400 beds in 40 states and Puerto Rico, serving more than 84,000 patients daily.

Business Model & Revenue Sources: The company generates revenue primarily from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and residential treatment. The facility mix includes:

• Acute inpatient psychiatric facilities (stabilizing patients who are a threat to themselves or others).
• Specialty treatment facilities (residential recovery for addictive disorders and co-occurring mental disorders).
• Comprehensive Treatment Centers (CTCs).
• Residential treatment centers.

Payor Mix: As of the year ended December 31, 2025, the revenue mix was heavily weighted toward government payors:

• Medicaid: 57.7%
• Commercial: 24.6%
• Medicare: 14.3%
• Other: 3.4%

Operational Activity (2025-2026):

• Bed Growth: During 2025, the company added 1,089 beds (311 to existing facilities, 778 via new openings) and closed 5 facilities totaling 382 beds.
• Facility Openings: In 2025, 15 CTCs were opened.
• 2026 Outlook: Management expects to open 2 facilities in Q2 2026 (a 144-bed JV with Orlando Health and a 96-bed facility with Methodus). In Q1 2026 alone, 82 beds were added, with a full-year target of adding 400 to 600 beds.
• Financial Performance: Revenue grew from $3,154.0 million in 2024 to $3,312.8 million in 2025.

4. Archetype and Conviction

Archetype: Quality Compounder Fit Analysis: The name fits the Quality Compounder archetype based on the consistent execution of bed expansion, revenue growth, and margin management.

• Margin Inflector: Management has explicitly stated confidence in delivering $200 million of adjusted EBITDA growth relative to 2025.
• Capital Efficiency: Despite the growth in beds, management is reducing capital investment by over $300 million compared to 2025, signaling a shift toward higher-return, lower-capex growth (likely via Joint Ventures).
• Guidance Upgrade: Full-year adjusted EBITDA guidance was raised from $575–$610 million to $580–$615 million, indicating management's confidence in the operational ramp-up.

Conviction Stack:

• Thesis Strength: Moderate (Tactical only, no macro tailwind named).
• Evidence Quality: High. Multiple primary sources (earnings transcripts and SEC filings) confirm bed growth, revenue expansion, and margin improvement.
• Setup Readiness: Partial. The structure is in place, but the breakout has not fired.
• Rerating Potential: Dependent on the confirmation of the $200M EBITDA growth and the successful execution of the JV strategy.

5. Invalidation, Strengthening, and Gaps

What Would Invalidate:

• Management guidance being cut below the current $580–$615 million EBITDA range.
• Regulatory disapproval of the programs currently under review (which could remove the potential $22 million incremental EBITDA).

What Would Strengthen:

• A confirmed breakout above the forming coil resistance (firing the conservative entry).
• Confirmation that the "certain programs under regulatory review" receive approval, unlocking the $22 million upside.
• Further evidence of successful JV execution (e.g., the Orlando Health and Methodus facilities opening on schedule).

Gaps in Evidence:

• Valuation Context: The provided evidence does not contain current P/E, EV/EBITDA, or DCF multiples. Without this, we cannot assess if the $24.87 price is rich or cheap relative to the $580–$615M EBITDA guidance.
• Debt Structure: No specific details on leverage ratios or interest coverage are provided in the evidence block, which is critical for a capital-intensive business model.
• Regulatory Specifics: While the $22M upside is mentioned, the specific nature of the "programs under regulatory review" is not detailed.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: Medium Key evidence: Management raised full-year adjusted EBITDA guidance to $580–$615 million; Company is reducing capital investment by over $300 million while adding 400–600 beds; Revenue grew to $3.31 billion in 2025 with consistent bed expansion. Key risks: Heavy reliance on Medicaid payors (57.7% of revenue); Regulatory uncertainty regarding programs that could add $22 million EBITDA; Setup is currently forming, not confirmed breakout. Sizing hint: Position size should reflect the "forming" status; smaller than a confirmed breakout, larger than a speculative long-only. Expected path: Management expects to open 2 JV facilities in Q2 and add 400–600 beds for the year; if the forming coil breaks out, the market will likely re-rate based on the $200 million EBITDA growth trajectory. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).